200 yuan a needle imported medicine sold 700,000! Netizen: Why does life-saving medicine not be included in zero tariffs and health insurance?

Introduction: 2020 is expected to be included in health insurance! Recently, a paper "cure" news circulated on the Internet, a "Oyang Chunlan" woman to the State Drug Administration to apply for more than 700,000 a sky-high price drug "Nosina sodium injection" information disclosure.
cause is that netizens pointed out that "Nosina sodium injection in the Chinese market needs 700,000 yuan, and in Australia only 41 Australian dollars (equivalent to about 205 yuan)," triggered the heat theory! What's the drug "Nosina sodium"? Nosina sodium is a precisely targeted treatment for spinal muscular dystrophy (Spinal Muscular, SMA).
spinal muscular dystrophy (SMA) is a common autosomal recessive genetic disease in childhood, mainly manifested in the development, symmetry of limbs and torso muscle weakness, atrophy, severe patients often die from respiratory failure and severe lung infection.
the incidence of the disease in newborns is about 1/10000 to 1/6000, the population carrying rate of 1/60 to 1/40, the Chinese group sMA carrying rate is about 1/42.
usually, 90 percent of babies with the disease do not live beyond the age of 2 or live on a ventilator forever.
Nosina sodium injection is an antisense oligonucleotide (ASO) developed using Ionis's proprietary antisense technology to treat SMA caused by mutations or deletions of the SMN1 gene (located on chromosome 5q), resulting in a lack of SMN proteins.
Nosina sodium injections can alter the splicing of sMN2 pre-mRNA, thereby increasing the production of the full length SMN protein.
Nosinasssin injections, developed by Ionis Pharmaceuticals, California, have been granted priority approval by the FDA for fast-track approval pathways, orphan drugs, and treatments for rare pediatric diseases;
August 8, 2018, CDE announced 48 overseas listed clinically in urgent need of new drugs, and Nusinersen is one of them; Why is the price so high
? According to media reports, in response to the telephone response of the State Drug Administration to the information disclosure application for the pricing of this drug, the State Drug Administration approved the import of this drug for treatment through the priority review and approval process, but it does not have the drug pricing power. on August 5,
, the State Health Insurance Administration office staff interviewed by the media, said that the price of nosina raw sodium is set by the drug companies, so the price of the drug in each country there is a certain difference, at the same time because Nosina raw sodium is a rare disease drug, drug company research and development costs are high, and in the patent period, in the short term to recover costs, to obtain effective profits to continue to increase drug research and development, this special effect or orphan drug pricing is high.
actually, The Nosina sodium injection is also expensive in the U.S., priced at $125,000 (about 870,000 yuan) a needle, the first year needs to be injected six times, the cost of treatment is about 750,000 U.S. dollars (about 5.2 million yuan), the cost of the second year reduced by half to 375,000 (about 2.6 million yuan).
This afternoon, the official WeChat issue of Yan Jian Bio responded to why domestic prices will be more expensive than in Australia, innosina sodium injection is currently a self-funded drug in China.
and according to public information available on the Australian Drug Welfare Scheme website, Nosina sodium injections have been included in the Drug Welfare Scheme, with the purchase price of the drug at A$110,000 and the patient paying A$41.
A$41 is not the price of a nosin sodium injection in Australia.
(with full official response) included in the health care negotiation agenda? It is reported that since the domestic market in 2019, Nosina sodium injection has been included in the health care negotiations agenda, the state hopes to negotiate with related drug companies, drug prices to lower, and thus meet the needs of SMA patients.
said in today's statement that according to the relevant national regulations, the drugs that participate in the 2019 national health insurance negotiations must be approved by December 31, 2018.
Nosina sodium injection was approved in February 2019 and did not qualify for the 2019 national health-care negotiations, so he did not participate in the 2019 national health-care negotiations. On August 3,
, the State Administration of Medical Security issued the "National Medical Insurance Drug Catalog Adjustment Work Programme (Draft for Comments)" notice, proposed to add seven new types of drugs into the medical insurance, including the third category "to include clinically urgentneeded list of new drugs abroad, encourage generic drugs catalog or encourage research and development to declare the list of children's drugs, and by December 31, 2019 by the State Drug Administration approved the listing of drugs."
"s hope this year's health-care overhaul will give it the opportunity to include the Nosina sodium injection, a larger level of welfare patients. what other SMA drugs are being developed
? According to pharmaceutical data, so far, a total of two drugs for the treatment of SMA have been approved for sale, in addition to the nosina sodium injection, another is Novartis Pharmaceuticals Zolgensma, Zolgensma was approved by the FDA in May 2019, not yet listed in the domestic market, because ZolgenSma is a potential one-time cure, Zolgensma is priced at $2.1 million.
, Zolgensma is currently only approved for SMAI-type treatment.
to make up for Zolgensma's lack of indications, Novartis subsidiary AveXis is actively conducting clinical trials in the hope of expanding the scope of approvals.
the details of the development of global SMA therapeutic drugs, Roche's risdiplam has also conducted clinical trials in China and is currently in Phase 2 clinical trials.
Risdiplam China clinical trial details table attached to the full official response: Yan Jian China notes some recent media reports on the spinal muscular dystrophy (SMA) treatment drug Nosina sodium injection, we explain here: SMA is a rare autosomal recessive neuromuscular disease.
Nosina sodium injection is the world's first approved SMA treatment.
As of June 30, 2020, Nosina sodium injections have been approved in 50 countries and territories around the world and have been reimbursed in more than 40 countries and regions, including Australia.
drug prices and out-of-pocket costs for patients after reimbursement are two completely different concepts.
according to the Australian Drug Benefit Scheme-PBS website, Nosina sodium injections have been included in the Drug Benefits Scheme, with a government purchase price of A$110,000 and a patient out-of-pocket fee of A$41.
A$41 is not the price of a nosin sodium injection in Australia.
in recent years, the state has issued a series of policies to speed up the approval of rare disease drugs, improve drug protection for rare patients, SMA, a rare disease, the first to benefit from the national policy on rare diseases.
May 2018, SMA was included in the National List of Rare Diseases.
November 2018, Nosina sodium injections were included in the First Batch of Clinically UrgentLy Needed New Drugs.
February 2019, The Nosinasssssin injections were approved in China through a priority review and approval process.
Nosina sodium injections are currently self-funded drugs in China.
's Yan Jian deeply understands the importance and urgency of addressing the payment challenge to The SMA patient community in China.
May 31, 2019, the China Primary Health Care Foundation announced the official launch of the SMA Patient Assistance Program, which is donated by Yan Jian.
the program helps SMA patients save about two-thirds of their first year of treatment compared to their full cost, and then save about half the annual cost of treatment compared to full cost.
So far, more than 80 SMA patients across the country have received medication with the help of aid programs.
in accordance with the relevant national regulations, the drugs participating in the 2019 national health insurance negotiations must be approved by December 31, 2018.
Nosina sodium injection was approved in February 2019 and did not qualify for the 2019 national health-care negotiations, so he did not participate in the 2019 national health-care negotiations.
has been actively communicating with relevant state and local government departments, calling for the establishment of a multi-payment mechanism to further enhance drug accessibility for SMA patients in China.
source: Yan Jian biological, medicine and intelligence network and other network public information.